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D
iabetes presents a vast worldwide 
socioeconomic burden; its disabilities 
reduce quality of life and result in 
enormous and increasing direct and indi­
rect medical costs (1-6). Although these 
costs result from a variety of factors, chronic 
complications account for more than 50% 
of the total costs for diabetes care; the 
remaining costs are for the treatment of dia­
betes per se (1,6,7). These complications 
can be significantly reduced by control of 
blood glucose and associated cardiovascular 
risk factors (10-12). For example, each 
10% increase in HbAlc is accompanied by a 
parallel 20% increase in the rate of microal­
buminuria, a 56% increase in the rate of 
retinopathy, and a 64% increase in the rate 
of progression of retinopathy (13).
Despite this clear and convincing evi­
dence of the feasibility and benefits of pre­
vention of chronic complications and the 
widely distributed guidelines for the care of 
diabetes (14,15), the current quality of care 
of people with diabetes is generally subop­
timal, even in developed nations (16,17). As 
the burden of diabetes increases, it is rea­
sonable to predict that the problem will get 
worse, because the increasing incidence and 
survival of patients with diabetes, combined 
with suboptimal care, will increase the 
prevalence of diabetes complications.
Diabetes presents a particular challenge 
to developing countries for many reasons. 
First, the incidence and prevalence of dia­
betes are increasing dramatically in devel­
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oping countries with westernization (18); 
the World Health Organization (WHO) esti­
mates that developing nations will have the 
largest prevalence of the disease in the near 
future (19). Second, 80% of the diabetes 
disability-adjusted life-years lost worldwide 
already occurs in developing countries (20). 
Third, despite increasing knowledge of and 
technologies for the control and treatment 
of diabetes and its complications, the cost of 
new technologies have made them inacces­
sible in developing countries. Lastly, many 
countries face serious constraints in their 
health budgets; allocation or reallocation of 
funds will require careful prioritization to 
resolve the critical problems that diabetes 
increasingly presents.
Unfortunately, health policy makers are 
frequently unaware of (or have failed to act 
upon) either the strong evidence for the 
role of lifestyle changes (e.g., adopting 
healthy lifestyle habits, increasing physical 
activity, and adhering to an appropriate 
diet [21,22]) in the primary prevention of 
type 2 diabetes or the therapeutic and edu­
cational strategies to prevent or delay dia­
betes complications.
To address this problem, representa­
tives from a wide variety of organizations, 
including WHO, the European Health 
Ministries, and various diabetes organiza­
tions, have issued a call for action in the 
Saint Vincent Declaration (23) to decrease 
the socioeconomic impact of diabetes. In 
the U.S., we have launched the National 
Diabetes Education Program (23,24). With 
a similar aim, organizations from the Amer­
icas have launched the Declaration of the 
Americas (25). These initiatives urge the 
development of educational programs and 
national plans for the prevention and treat­
ment of diabetes, and they have established 
the minimum international standards for 
the care of people with diabetes.
What are the realistic alternatives to 
achieve the goal of reducing the 
social and economic burden of 
diabetes in developing countries?
It is difficult to answer fairly the question of 
how to define and assure quality diabetes 
care or how to appropriately allocate funds 
to support quality assurance. Diabetes care 
researchers and investigators have certainly 
provided us the evidence and the tools to 
solve the problem (10-12,26-30). It has 
also been shown that implementation of 
diabetes care programs at the national, 
provincial, or county levels and the use of 
prevention strategies taught by health care 
teams can result in two main objectives: the 
improvement of quality of care and the opti­
mization of human and economic resources. 
Such programs (e.g., DIABCARE [31] in 
Europe and PRODIABA [32] and PROPAT 
[33] in Argentina) reduce the cost of care 
and improve quality of life and patient satis­
faction. In this context, the cost of the solu­
tion—at least for decision makers and health 
ministries—is a major barrier because they 
will need to allocate or reallocate current 
resources. Such a task will require the real- 
location of resources today in order to liber­
ate resources tomorrow, which, of course, is 
never a popular political alternative.
In the U.S. and in many European 
countries, data are readily available to 
assess current costs of diabetes care and its 
quality (1,34). Even so, there are ongoing 
debates about how to define optimal care in 
these countries. In many developing coun­
tries, even the most basic figures on costs 
are unavailable. Furthermore, we contend 
that most if not all policy makers in devel-
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oping countries do not know how costly a 
burden the disease is on their health care 
system, how effective (or ineffective) cur­
rent diabetes treatment strategies are for 
diabetic subjects, and how diabetes care 
could be optimized.
Thus, we will have to develop strategies 
that bridge the gap between scientific 
knowledge and the real world. To accom­
plish this (i.e., the reallocation funds to the 
prevention and treatment of diabetes), we 
will have to provide clear evidence (cost­
benefits and cost-efficacy) to convince health 
policy makers to support such a reallocation. 
Therefore, all members of diabetes commu­
nity need to be aware that every allocation of 
funds is the result of vigorous competition 
among several priorities resulting from the 
pressing economic state of the health care 
systems of developing countries.
What can be done to help those 
countries to overcome such a lack of 
information?
Starting with the basics, it is known that, in 
most countries, diabetes consumes 
between 5 and 10% of the health budget 
and that ~50% or more of that cost is 
related to hospitalization (1,34,35). Esti­
mation of the total direct cost of diabetes is 
not an easy task, but cost of hospitalization 
can be estimated. Using a relatively simple 
protocol, hospitalization causes, rates, and 
length of stay (and its subsequent cost) 
could be useful indicators to measure effi­
cacy of current care and any intervention 
implemented to improve quality of care. 
Measurement of hospitalization rates and 
costs could also provide the basic data to 
estimate the indirect costs related to loss of 
production. Thus, determination of hospi­
tal costs could provide a useful tool, a tracer 
if you will, to estimate a significant portion 
of the current costs of caring for diabetes 
and its complications in a given country or 
area within a country, thereby providing the 
basis for designing, implementing, and 
evaluating intervention strategies and set­
ting priorities for resource allocation.
Is this strategy feasible, and, if so, 
how it could be accomplished?
Recently, WHO and the International Dia­
betes Federation (IDF) Task Force on Dia­
betes Health Economics prepared a 
document that broadly outlined the world­
wide economics of diabetes and diabetes 
care (2). Distribution of this information to 
health policy makers would certainly be an 
excellent beginning to implementing the 
strategy. The same group provided an 
update that included both information on 
costs and the effectiveness of interventions 
(36). In addition, this group, in collabora­
tion with the Diabetes Health Economics 
Study Group, possesses sufficient exper­
tise to prepare a simple and suitable proto­
col to approach the problem and to study 
the cost of diabetes hospitalization. They 
could also train people for its appropriate 
usage and organize and lead an interna­
tional multicenter study with participation 
by representatives from many countries. 
Emphasis could be placed on recruiting 
groups from developing countries.
The resultant estimations of hospital 
costs of diabetes in developing countries 
would allow us to evaluate the costs and 
benefits of the implementation of strategies 
designed to improve diabetes care and to 
reduce its complications. These data will be 
critical in the debate over appropriate allo­
cation of funds to treat diabetes and pre­
vent complications. We urge the IDF Task 
Force on Diabetes Health Economics in 
collaboration with the Diabetes Health Eco­
nomics Study Group to continue their 
work in the development and implementa­
tion of a protocol to study the cost of dia­
betes hospitalization in developing 
countries. Failure to act now will mean 
that we will be dealing with the avoidable 
burden of diabetes complications in the 
new century.
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